On Monday, September 12th, 2016 at AEI, health policy experts representing practitioners and industry discussed the issue of high drug prices.

On the panel, Precision Health Economics’ Tomas Philipson cast doubt on the claim that research and development determine pricing, arguing that in reality causality runs in the opposite direction. He noted potential flaws in value-based pricing and a one-size-fits-all-approach to global drug development and argued for more robust credit markets in health care.